J. Carser

An Association of Cancer Physicians’ strategy for improving services and outcomes for cancer patients

Jeff White, H. Earl, D. Eccles, 2016, Ecancermedicalscience.

Trichomegaly of the eyelashes after treatment with erlotinib in non-small cell lung cancer.

Y. Summers, J. Carser, 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The use of tacrolimus in the management of checkpoint inhibitor immunotherapy-induced hepatitis

J. Cash, J. Carser, L. Stratton, 2022, Journal of the Royal College of Physicians of Edinburgh.

Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol

Warren C. Grant, M. Parmar, M. Sydes, 2021, The Lancet.

The impact of a new acute oncology service in acute hospitals: experience from the Clatterbridge Cancer Centre and Merseyside and Cheshire Cancer Network.

H. Wong, E. Marshall, H. Neville-Webbe, 2013, Clinical medicine.

BRCA1 is both a prognostic and predictive biomarker of response to chemotherapy in sporadic epithelial ovarian cancer.

P. Maxwell, C. Gourley, R. Kennedy, 2011, Gynecologic oncology.

BRCA1 and implications for response to chemotherapy in ovarian cancer.

R. Kennedy, D. Harkin, C. James, 2009, Gynecologic oncology.

BRCA1 protein expression as a predictor of outcome following chemotherapy in sporadic epithelial ovarian cancer (EOC).

C. Gourley, P. Mullan, D. Harkin, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial.

V. Goh, T. Powles, M. Highley, 2023, The Lancet. Oncology.